Last reviewed · How we verify
Inactivated HAV vaccine
The Inactivated HAV vaccine, marketed by Sinovac Biotech Co., Ltd, holds a significant position in the hepatitis A vaccination market. The key composition patent, set to expire in 2028, provides a strong competitive barrier until then. The primary risk is the potential increase in competition following the patent expiry.
At a glance
| Generic name | Inactivated HAV vaccine |
|---|---|
| Also known as | Inactivated hepatitis A vaccines |
| Sponsor | Sinovac Biotech Co., Ltd |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines (PHASE4)
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
- BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies (PHASE3)
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (PHASE2)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Immunogenicity of 2 Versus 3 Doses of Combined Hepatitis B Vaccines in 2-18 Months Old Children (PHASE4)
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inactivated HAV vaccine CI brief — competitive landscape report
- Inactivated HAV vaccine updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI